Furthermore, the compound LY294002, which inhibits the AKT/mTOR signaling pathway, was able to reverse the enhanced proliferation, migration, and invasion capabilities produced by the suppression of TRIM26 in ccRCC cells. This evidence concerns the gene TRIM26 and nonpapillary renal cell carcinoma.